Cargando…

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the risk of diabetic ketoacidosis (DKA) in patients remains unclear. The purpose of this study is to conduct this systema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Shiwen, Liu, Ying, Zhang, Shengzhao, Wu, Fengbo, Liu, Dan, Wu, Qingfang, Zheng, Hanrui, Fan, Ping, Su, Na
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311413/ https://www.ncbi.nlm.nih.gov/pubmed/37397500 http://dx.doi.org/10.3389/fphar.2023.1145587

Ejemplares similares

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

SGLT-2 Inhibitors—a Culprit of Diabetic Ketoacidosis Postbariatric Surgery
por: Iqbal, Qasim Zafar, et al.
Publicado: (2020)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Sodium-Glucose Co-Transporter-2 Inhibitors in Non-Diabetic Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis
por: Zheng, Hanrui, et al.
Publicado: (2021)

SGLT2 Inhibitor–Induced Euglycemic Diabetic Ketoacidosis: A Case Report
por: Wang, Katherine M., et al.
Publicado: (2020)

Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2‐inhibitor therapy
por: Westcott, Gregory P., et al.
Publicado: (2020)

Clinical Characteristics and Outcomes of Diabetic Ketoacidosis in Patients With Type 2 Diabetes using SGLT2 Inhibitors
por: Almazrouei, Raya, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis Secondary to SGLT2-inhibitor Use in Combination With a Ketogenic Diet
por: Hester, Joi C, et al.
Publicado: (2021)

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
por: Ogawa, Wataru, et al.
Publicado: (2015)

PSUN190 Is Euglycemic Diabetic Ketoacidosis an Underrecognized Risk of SGLT2 Inhibitor Utilization?
por: Block, Romy, et al.
Publicado: (2022)

THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023)

Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors
por: Vitale, Rebecca J., et al.
Publicado: (2020)

MON-690 Euglycemic Diabetic Ketoacidosis Associated with SGLT-2 Inhibitors- an Under-recognized Diagnosis
por: Chhabra, Sarah, et al.
Publicado: (2020)

Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors: A systematic review and quantitative analysis
por: Dutta, Siddhartha, et al.
Publicado: (2022)

A Case Report of Euglycemic Diabetic Ketoacidosis in the Setting of Keto Diet and SGLT-2 Inhibitors
por: Marenych, Nadiia, et al.
Publicado: (2021)

Nephrology Consultation for Severe SGLT2 Inhibitor-Induced Ketoacidosis in Type 2 Diabetes: Case Report
por: Nappi, Felice, et al.
Publicado: (2019)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors
por: Limenta, Michael, et al.
Publicado: (2019)

Clinical Outcomes of Diabetic Ketoacidosis in Type 2 Diabetes Patients with and without SGLT2 Inhibitor Treatment: A Retrospective Study
por: Nakhleh, Afif, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

ODP183 Diabetic Ketoacidosis Precipitated by Ketogenic Diet and SGLT-2 Inhibitor Use in an Individual with T2DM
por: Mason, Timothy, et al.
Publicado: (2022)

Euglycemic Diabetic Ketoacidosis Precipitated by SGLT-2 Inhibitor Use, Pericarditis, and Fasting: A Case Report
por: Mendelsohn, Rebecca A., et al.
Publicado: (2020)

SAT-685 Euglycemic Diabetic Ketoacidosis in T1d: The Era of SGLT-2 Inhibitors and Keto-Diet
por: Castellanos-Diaz, Jessica, et al.
Publicado: (2020)

SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report
por: Secinaro, Enzo, et al.
Publicado: (2022)

SGLT-2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report and a Literature Review
por: Mahfooz, Rabia Salman, et al.
Publicado: (2022)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

Diabetic Euglycemic Ketoacidosis Induced by Oral Antidiabetics Type SGLT2i
por: Velasco de Cos, Guillermo, et al.
Publicado: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
por: Zhang, Yu, et al.
Publicado: (2023)

Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism
por: Xie, Lingxiang, et al.
Publicado: (2022)

COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report
por: Batista, Daniel Valente, et al.
Publicado: (2020)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
por: Xing, Yu-jie, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis in the Setting of SGLT2 Inhibitor Use and Hypertriglyceridemia: A Case Report and Review of Literature
por: Gajjar, Kushani, et al.
Publicado: (2019)

A Case of SGLT2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis Following Coronary Artery Bypass Surgery
por: Osafehinti, Deborah A., et al.
Publicado: (2020)

Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma
por: Ahmed, Taha, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lob9l09i4qprtpabgpri1mpl6v